Understanding the patient journey is paramount for recruiting and engaging study participants. At Allucent, we have specialized expertise in this area, gained over many years working across a range of therapeutic areas and clinical study types, including on-site, decentralized, and hybrid trials. Throughout the duration of your trial, you will work directly with a patient recruitment specialist on our team, who will serve as your single point of contact and liaison with other experts at Allucent.
Our approach involves developing a comprehensive recruitment plan tailored for your study that is patient centric, data driven, and site specific. This plan encompasses enrollment projections, description of the strategies and timing of implementation, and actions to mitigate risks. Our intent is to ensure enrollment certainty and achieve on-time delivery. Key to planning your trial is developing a patient profile that identifies the characteristics of the target population while anticipating the potential burdens in order to make participation as attractive and obstacle-free as possible. This is especially critical in rare disease, where trials often involve children and families who might not live within easy travel range of the site. In these cases, Allucent offers concierge services to support patients and families as needed.
Allucent offers tailored strategies to support recruitment, engagement, and compliance, depending on the specific parameters of your initiative. For example, regarding recruitment, we are able to devise an outreach strategy that might entail use of registries, partnerships with patient advocacy groups and key opinion leaders, and on-site communications. We aim to meet your objectives while choosing tactics most appropriate for your study, timeline, and budget. We empower sites through training and education to enroll patients in your study as quickly as possible.
Your program is customized according to country regulations and sites capabilities. Using in-house resources, Allucent manages production of patient-facing materials, including translation and IRB/EC approval as necessary.